Your browser is no longer supported. Please, upgrade your browser.
Settings
ALBO Albireo Pharma, Inc. daily Stock Chart
ALBO [NASD]
Albireo Pharma, Inc.
Index- P/E- EPS (ttm)-2.57 Insider Own0.50% Shs Outstand13.01M Perf Week2.32%
Market Cap343.98M Forward P/E- EPS next Y-3.98 Insider Trans-26.28% Shs Float9.81M Perf Month-6.77%
Income-27.80M PEG- EPS next Q-0.99 Inst Own82.10% Short Float4.51% Perf Quarter-12.94%
Sales11.90M P/S28.91 EPS this Y76.30% Inst Trans0.49% Short Ratio10.90 Perf Half Y-19.39%
Book/sh11.42 P/B2.32 EPS next Y-17.10% ROA- Target Price63.50 Perf Year3.40%
Cash/sh13.34 P/C1.98 EPS next 5Y- ROE- 52W Range21.25 - 39.87 Perf YTD3.28%
Dividend- P/FCF- EPS past 5Y39.00% ROI- 52W High-33.68% Beta1.81
Dividend %- Quick Ratio19.40 Sales past 5Y- Gross Margin- 52W Low24.42% ATR2.26
Employees22 Current Ratio19.40 Sales Q/Q72900.00% Oper. Margin- RSI (14)45.00 Volatility8.49% 8.40%
OptionableYes Debt/Eq0.00 EPS Q/Q-60.00% Profit Margin- Rel Volume0.91 Prev Close25.68
ShortableYes LT Debt/Eq0.00 EarningsNov 13 BMO Payout- Avg Volume40.56K Price26.44
Recom1.40 SMA20-2.55% SMA50-10.47% SMA200-17.87% Volume36,926 Change2.96%
Apr-20-18Initiated Jefferies Buy $50
Nov-15-17Initiated ROTH Capital Buy $92
Jul-18-17Initiated Needham Buy $35
Jun-30-17Initiated Wedbush Outperform $58
Feb-16-17Initiated Ladenburg Thalmann Buy $40
Nov-13-18 07:00AM  Albireo Reports Third Quarter 2018 Financial Results GlobeNewswire
Nov-08-18 08:30AM  Albireo to Present at Investor Conferences in November GlobeNewswire
Nov-06-18 08:30AM  Albireo to Report Third Quarter 2018 Financial Results and Host Conference Call and Webcast on November 13, 2018 GlobeNewswire
Nov-04-18 09:24PM  Hedge Fund Governors Lane Is Betting On A Seth Klarman Favorite Insider Monkey
Oct-26-18 09:00AM  Report: Exploring Fundamental Drivers Behind Manulife Financial, Baozun, AstraZeneca, Insight Enterprises, Albireo Pharma, and Mobile TeleSystems OJSC New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Oct-17-18 08:30AM  Albireo Receives FDA Fast Track Designation for A4250 GlobeNewswire
08:30AM  Albireo Granted Orphan Drug Designation For Lead Product Candidate A4250 for Treatment of Alagille Syndrome GlobeNewswire
Oct-15-18 08:30AM  Albireo Announces Research on Cholestatic Liver Diseases to be Presented at Major North American Liver Meetings GlobeNewswire +8.34%
Oct-10-18 08:30AM  Albireo Appoints Simon Harford as Chief Financial Officer and Treasurer GlobeNewswire -8.86%
Sep-25-18 07:30AM  Factors of Influence in 2018, Key Indicators and Opportunity within Pentair plc, Albireo Pharma, Cardlytics, New Oriental Education & Technology Group, State Street, and Axis Capital New Research Emphasizes Economic Growth GlobeNewswire
Sep-24-18 08:30AM  Albireo to Present at Cantor Fitzgerald Global Healthcare Conference GlobeNewswire
Aug-29-18 08:30AM  Albireo to Present at the H.C. Wainwright Global Investment Conference GlobeNewswire
Aug-08-18 08:30AM  Albireo to Present at Wedbush PacGrow Healthcare Conference GlobeNewswire
Aug-07-18 07:30AM  Albireo Reports Second Quarter 2018 Financial Results GlobeNewswire -7.13%
06:30AM  Albireo Pharma, Inc. to Host Earnings Call ACCESSWIRE
Aug-02-18 04:01PM  Albireo to Report Second Quarter 2018 Financial Results, and Host Conference Call and Webcast on August 7, 2018 GlobeNewswire
Jul-31-18 07:45AM  Factors of Influence in 2018, Key Indicators and Opportunity within Finisar, Albireo Pharma, Corporate Office Properties Trust, Ocean Power Technologies, Depomed, and Potbelly New Research Emphasizes Economic Growth GlobeNewswire
Jul-25-18 08:30AM  Albireo Appoints Patrick Horn MD, PhD as Chief Medical Officer GlobeNewswire
Jun-25-18 08:30AM  Albireo Added to Russell 2000® Index GlobeNewswire -6.27%
Jun-18-18 08:30AM  Albireo Appoints Jason G. Duncan as General Counsel and Secretary GlobeNewswire
Jun-12-18 08:30AM  FDA Grants Rare Pediatric Disease Designation to A4250; Albireo Eligible to Apply for Priority Review Voucher GlobeNewswire
Jun-08-18 09:00AM  Albireo Elects Anne Klibanski and Stephanie Okey to Board of Directors GlobeNewswire
May-29-18 08:00AM  Albireo to Present at Jefferies 2018 Global Healthcare Conference GlobeNewswire
May-24-18 07:20AM  Blog Exposure - Trevena Showcases Data from ATHENA Phase-3 Study at the American Society of Colon and Rectal Surgeons 2018 Annual Scientific Meeting ACCESSWIRE
May-17-18 07:30AM  Albireo Provides First Quarter 2018 Business Update GlobeNewswire
06:30AM  Albireo Pharma, Inc. to Host Earnings Call ACCESSWIRE
May-16-18 08:30AM  Albireo Enrolls First Patient in Phase 3 PFIC Trial of A4250 GlobeNewswire +7.52%
May-09-18 08:00AM  Albireo to Host First Quarter 2018 Business Update Conference Call and Webcast on May 17, 2018 GlobeNewswire
Apr-30-18 08:00AM  Albireo to Present at Deutsche Bank 43rd Annual Health Care Conference GlobeNewswire
Apr-19-18 08:00AM  Albireo to Present Data from Two Studies on Cholestatic Liver Disease at the 51st ESPGHAN Annual Meeting GlobeNewswire
Apr-14-18 08:00AM  Albireo Reports Data on Pharmacodynamic Marker for A4250 in Children with Cholestatic Liver Disease at The International Liver Congress 2018 GlobeNewswire
Apr-03-18 08:00AM  Albireo Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Apr-02-18 08:00AM  Albireo to Present at H.C. Wainwright Global Life Sciences Conference GlobeNewswire
Mar-28-18 08:00AM  Albireo to Present Clinical Data on A4250 at The International Liver Congress 2018 GlobeNewswire
Mar-21-18 08:00AM  Albireo to Present at 17th Annual Needham & Company Healthcare Conference GlobeNewswire
07:30AM  Wired News Agios Pharmaceuticals Doses First Patient in AG-270 Phase-1 Dose-Escalation Trial in MTAP-Deleted Tumors ACCESSWIRE
Mar-20-18 07:30AM  Wired News Zosano Reports Enrollment Milestone in its M207-ADAM Study ACCESSWIRE
Mar-15-18 07:30AM  Albireo Reports Fourth Quarter and Year-End 2017 Financial Results GlobeNewswire
06:40AM  Albireo Pharma, Inc. to Host Earnings Call ACCESSWIRE
Mar-08-18 08:00AM  Albireo to Report Fourth Quarter and Year-End 2017 Financial Results and Host Conference Call and Webcast on March 15, 2018 GlobeNewswire
Mar-06-18 08:00AM  Albireo to Present at 38th Annual Cowen and Company Health Care Conference GlobeNewswire
Jan-29-18 04:01PM  Albireo Announces Closing of $74.8 Million Public Offering Including Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire +5.78%
Jan-26-18 04:48PM  Largest Insider Trades of the Week GuruFocus.com +8.29%
Jan-25-18 08:45AM  Albireo Prices $65.0 Million Public Offering of Common Stock GlobeNewswire
Jan-24-18 04:01PM  Albireo Announces Proposed Public Offering of Common Stock GlobeNewswire
Jan-19-18 08:00AM  Albireo to Receive More than $55 Million(1) in Nondilutive Cash Payments GlobeNewswire +11.98%
Jan-03-18 08:00AM  Albireo Announces Royalty Monetization Agreement with HealthCare Royalty Partners for Elobixibat in Japan GlobeNewswire
Dec-29-17 08:00AM  Albireo Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Dec-05-17 05:02PM  [$$] AstraZeneca Sells $10.7 Million in Albireo Stock Barrons.com
Nov-14-17 08:00AM  Albireo Reports Third Quarter 2017 Financial Results GlobeNewswire -10.73%
Nov-09-17 08:00AM  Albireo to Present at the Jefferies 2017 London Healthcare Conference GlobeNewswire
Oct-24-17 07:30AM  Featured Company News - Albireo Pharma to Present Final Results of Phase-2 Study of A4250 in Children with Cholestatic Liver Disease at The Liver Meeting(R) 2017 ACCESSWIRE
Oct-20-17 08:00AM  Final Results of Albireos Phase 2 Study of A4250 in Children with Cholestatic Liver Disease Presented at The Liver Meeting® 2017 GlobeNewswire
Oct-16-17 08:00AM  Albireo to Host KOL Event on Progressive Familial Intrahepatic Cholestasis GlobeNewswire
Oct-03-17 08:00AM  Final Results of Albireos Phase 2 Study of A4250 in Children with Cholestatic Liver Disease to be Presented at The Liver Meeting® 2017 GlobeNewswire
Sep-28-17 08:00AM  Albireo Elects Roger Jeffs to Board of Directors GlobeNewswire
Sep-26-17 08:00AM  EMAs Paediatric Committee Agrees to Albireos A4250 Pediatric Investigation Plan GlobeNewswire -6.38%
Sep-19-17 08:24AM  Albireo to Present at Investor Conferences in September GlobeNewswire
07:10AM  Featured Company News - RXi Pharma's Chief Business Officer, Alexey Eliseev, to Leave the Company ACCESSWIRE
Sep-05-17 08:00AM  Albireo to Present at 19th Annual Rodman & Renshaw Global Investment Conference GlobeNewswire -11.10%
Aug-21-17 08:36AM  Albireo Reports Second Quarter 2017 Financial Results GlobeNewswire
Aug-08-17 08:00AM  Albireo to Present at Wedbush PacGrow Healthcare Conference GlobeNewswire
May-30-17 04:01PM  Albireo Announces Closing of $51.9 Million Public Offering Including Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire +14.00%
May-24-17 08:39AM  Albireo Prices $45.1 Million Public Offering of Common Stock GlobeNewswire
May-23-17 04:01PM  Albireo Announces Proposed Public Offering of Common Stock GlobeNewswire
May-18-17 08:00AM  Albireo Announces Plans for Phase 3 Clinical Program of A4250 in Patients with PFIC GlobeNewswire
May-16-17 08:00AM  Albireo Announces Two New U.S. Patents Allowed for A4250 with Term into 2031 GlobeNewswire
May-10-17 04:01PM  Albireo Reports First Quarter 2017 Financial Results GlobeNewswire
Apr-27-17 08:00AM  Albireo Announces Elobixibat Data from Japan to be Presented at DDW 2017 GlobeNewswire
Apr-22-17 01:00AM  Promising Pediatric Data for Albireos A4250 to be Presented at The International Liver Congress 2017 GlobeNewswire
Apr-10-17 08:00AM  Albireo to Host KOL Meeting on Rare Pediatric Liver Diseases on April 12 GlobeNewswire
Apr-05-17 08:00AM  EASL Selects Albireos A4250 Data for Late Breaker Presentation GlobeNewswire
08:00AM  EASL Selects Albireos A4250 Data for Late Breaker Presentation
Mar-31-17 01:04PM  ALBIREO PHARMA, INC. Financials
Mar-28-17 08:00AM  Albireo to Present at Upcoming Investor Conferences GlobeNewswire
Mar-14-17 07:36AM  ALBIREO PHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhi -6.71%
07:30AM  Albireo Reports 2016 Financial Results GlobeNewswire
Mar-07-17 08:00AM  Albireo to Host Conference Call and Webcast on March 14 at 8:30 a.m. ET to Discuss Year-End 2016 Financial Results and Operational Highlights GlobeNewswire
Mar-01-17 08:00AM  Albireo to Present at 37th Annual Cowen and Company Health Care Conference GlobeNewswire
Feb-16-17 07:00AM  Coverage initiated on Albireo Pharma by Ladenburg Thalmann +11.39%
Feb-10-17 04:33PM  ALBIREO PHARMA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial O
Feb-06-17 08:00AM  Albireo to Present at 19th Annual BIO CEO & Investor Conference GlobeNewswire
Feb-01-17 08:00AM  Albireo Announces Submission of New Drug Application for Elobixibat in Japan GlobeNewswire
Jan-27-17 05:01PM  ALBIREO PHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Dec-30-16 01:04PM  ALBIREO PHARMA, INC. Financials
Dec-22-16 04:06PM  ALBIREO PHARMA, INC. Files SEC form 8-K/A, Financial Statements and Exhibits +8.18%
04:03PM  ALBIREO PHARMA, INC. Files SEC form 10-K, Annual Report
Dec-21-16 05:10PM  ALBIREO PHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits -7.33%
Dec-16-16 04:32PM  ALBIREO PHARMA, INC. Files SEC form 8-K/A, Financial Statements and Exhibits -5.45%
Nov-29-16 08:00AM  Albireo Expands Team, Appoints Martha J. Carter as Chief Regulatory Officer GlobeNewswire
Nov-16-16 04:50PM  LifeSci Capital Initiates Coverage of Albireo Accesswire
Nov-15-16 09:01AM  Albireos Lead Product Candidate for Orphan Pediatric Liver Disease Accepted Into European Medicines Agencys PRIME Program GlobeNewswire +12.54%
Nov-04-16 05:09PM  ALBIREO PHARMA, INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Creation of a Direct Fin
Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate includes A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases. The company also develops Elobixibat, an orally administered IBAT inhibitor for the treatment of chronic constipation and other GI diseases, as well as nonalcoholic steatohepatitis; and A3384 for the treatment of bile acid malabsorption. It has license agreement with EA Pharma for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cooper Ronald Harold WilfredPresident and CEONov 13Buy25.021,02625,6687,760Nov 15 04:12 PM
Cooper Ronald Harold WilfredPresident and CEOAug 14Buy31.8578825,0986,734Aug 16 04:26 PM
Mattsson JanChief Operating OfficerJun 13Sale32.086,903221,44834,214Jun 14 07:49 PM
Mattsson JanChief Operating OfficerJun 12Sale32.3318,097585,06041,117Jun 14 07:49 PM
BROWN JULIA RDirectorJun 07Option Exercise9.003,33329,9977,833Jul 06 04:17 PM
BROWN JULIA RDirectorJun 07Option Exercise17.554,50078,9604,500Jun 11 04:08 PM
Phase4 Partners Ltd10% OwnerJan 30Sale34.44100,0003,444,0471,065,447Feb 01 04:48 PM
PERCEPTIVE ADVISORS LLC10% OwnerJan 25Buy33.00275,0009,075,0001,595,000Jan 25 04:59 PM
ASTRAZENECA PLC10% OwnerDec 01Sale21.40500,00010,700,000508,141Dec 05 04:18 PM